Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

NIOX Group a ‘Buy’ with Dependable Growth and Cashflow, Singer (LON: NIOX) 

NIOX continues to capitalise on both clinical and research markets, delivering consistent growth and strengthening its cash position...

One Health reshaping surgical care across northern England

One Health Group is steadily extending NHS‑backed elective care in northern England, underpinned by a 23% revenue surge and a funded surgical hub...

Aptamer advances liver fibrosis therapy with targeted gene delivery

Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells...

One Health Group Record Patient Growth and a Strategic Leap with New Surgical Hubs (Video)

One Health Group CEO Adam Binns shares how record NHS patient numbers, a successful AIM listing, and the upcoming launch of their first surgical hub are fuelling the company’s growth—and why this is just the beginning...

Healthcare real‑estate innovation

Physicians Capital, led by orthopaedic surgeon Dr Conrad Ivie, is redefining medical real estate by empowering clinician practices through tailored capital solutions...

Aptamer signs licensing deal for Optimer®-Fc diagnostic reagent

Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth...

AstraZeneca Secures U.S. FDA Accelerated Approval for Datroway in EGFR-Mutated NSCLC

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer..

One Health Group reports 23% growth and surgical hub plans

One Health Group continues to expand capacity for NHS-funded care through Patient Choice, backing waiting list reduction via surgical hubs and longer-term agreements with commissioners...

GSK Plc files to broaden Arexvy use in Japan

GSK's RSV vaccine has gained regulatory approval in Japan for adults aged 18-49 at increased risk, expanding protection against this common respiratory virus...

Where structure meets silent demand

Explore the rising importance of urology in healthcare, where effective management of the genitourinary system meets growing patient demands for quality and efficiency...

Syncona proposes investment policy change

Syncona Limited is revamping its investment strategy to enhance shareholder value amid challenging biotech market conditions. Explore their proposed policy changes and cash return options...

EDX Medical and Spire Healthcare sign MOU for diagnostic partnership

EDX Medical Group has partnered with Spire Healthcare to enhance digital diagnostics for cancer and other diseases, promising innovative patient care and improved outcomes...

Smith & Nephew appoints David King as Non-Executive Director

Smith & Nephew Plc announces the addition of David King as an independent Non-Executive Director, effective July 1, 2025, enhancing their healthcare leadership...

GSK Plc seeks EMA approval for RSV vaccine in adults 18+

GSK's RSV vaccine, Arexvy, is set for expanded use in adults 18+, following EMA's acceptance. This breakthrough addresses a critical need in respiratory health...

Empowering patient choice in healthcare

In an evolving healthcare landscape, One Health Group champions patient empowerment by offering flexible self-referral and GP referral options for tailored medical care...

AstraZeneca Plc secures EU approval for fixed-term CLL regimen

AstraZeneca's Calquence, combined with venetoclax, has received EU approval for treating untreated chronic lymphocytic leukaemia, showing promising trial results...

One Health targets rising demand in specialist foot and ankle care

Discover One Health Group's growth in the UK elective healthcare market, focusing on foot and ankle surgery, and how it presents investment opportunities...

GSK Plc launches second tranche of £2 billion Share Buyback

GSK plc launches a £2 billion share buyback program to enhance shareholder value, starting the second tranche valued at £0.45 billion on June 4, 2025...

Aptamer expands odour control collaboration with Unilever

Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market...
Search

Funds

Health

NIOX Group a ‘Buy’ with Dependable Growth and Cashflow, Singer (LON: NIOX) 

NIOX continues to capitalise on both clinical and research markets, delivering consistent growth and strengthening its cash position...

One Health reshaping surgical care across northern England

One Health Group is steadily extending NHS‑backed elective care in northern England, underpinned by a 23% revenue surge and a funded surgical hub...

Aptamer advances liver fibrosis therapy with targeted gene delivery

Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells...

One Health Group Record Patient Growth and a Strategic Leap with New Surgical Hubs (Video)

One Health Group CEO Adam Binns shares how record NHS patient numbers, a successful AIM listing, and the upcoming launch of their first surgical hub are fuelling the company’s growth—and why this is just the beginning...

Healthcare real‑estate innovation

Physicians Capital, led by orthopaedic surgeon Dr Conrad Ivie, is redefining medical real estate by empowering clinician practices through tailored capital solutions...

Aptamer signs licensing deal for Optimer®-Fc diagnostic reagent

Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth...

AstraZeneca Secures U.S. FDA Accelerated Approval for Datroway in EGFR-Mutated NSCLC

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer..

One Health Group reports 23% growth and surgical hub plans

One Health Group continues to expand capacity for NHS-funded care through Patient Choice, backing waiting list reduction via surgical hubs and longer-term agreements with commissioners...

GSK Plc files to broaden Arexvy use in Japan

GSK's RSV vaccine has gained regulatory approval in Japan for adults aged 18-49 at increased risk, expanding protection against this common respiratory virus...

Where structure meets silent demand

Explore the rising importance of urology in healthcare, where effective management of the genitourinary system meets growing patient demands for quality and efficiency...

Syncona proposes investment policy change

Syncona Limited is revamping its investment strategy to enhance shareholder value amid challenging biotech market conditions. Explore their proposed policy changes and cash return options...

EDX Medical and Spire Healthcare sign MOU for diagnostic partnership

EDX Medical Group has partnered with Spire Healthcare to enhance digital diagnostics for cancer and other diseases, promising innovative patient care and improved outcomes...

Smith & Nephew appoints David King as Non-Executive Director

Smith & Nephew Plc announces the addition of David King as an independent Non-Executive Director, effective July 1, 2025, enhancing their healthcare leadership...

GSK Plc seeks EMA approval for RSV vaccine in adults 18+

GSK's RSV vaccine, Arexvy, is set for expanded use in adults 18+, following EMA's acceptance. This breakthrough addresses a critical need in respiratory health...

Empowering patient choice in healthcare

In an evolving healthcare landscape, One Health Group champions patient empowerment by offering flexible self-referral and GP referral options for tailored medical care...

AstraZeneca Plc secures EU approval for fixed-term CLL regimen

AstraZeneca's Calquence, combined with venetoclax, has received EU approval for treating untreated chronic lymphocytic leukaemia, showing promising trial results...

One Health targets rising demand in specialist foot and ankle care

Discover One Health Group's growth in the UK elective healthcare market, focusing on foot and ankle surgery, and how it presents investment opportunities...

GSK Plc launches second tranche of £2 billion Share Buyback

GSK plc launches a £2 billion share buyback program to enhance shareholder value, starting the second tranche valued at £0.45 billion on June 4, 2025...

Aptamer expands odour control collaboration with Unilever

Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market...
Search

Funds

Health

FTSE 100

Funds